Belararox Limited extends agreement with Chemopharm Limited

Belararox Limited (ASX:BRX) has announced the extension of the end date of the term sheet with Chemopharm Limited for the acquisition of the Solwezi East and Chantente exploration licences in the Zambian Copperbelt. The new end date has been extended from 31 December 2023 to 15 April 2024 to allow Chemopharm to secure the Mining Licences. Additionally, Belararox has agreed to contribute US$20,000 to Chemopharm's expenses if the Mining Licences are acquired.

Executive Commentary

We are pleased to have reached an agreement with Chemopharm to extend the end date of the term sheet. This extension demonstrates our commitment to the acquisition of the exploration licences in the Zambian Copperbelt. We believe that providing financial support to Chemopharm's expenses aligns with our strategic goals and strengthens our partnership with them. We look forward to the potential acquisition of the Mining Licences and the opportunities they may bring to our company.

Summary

Belararox Limited (ASX:BRX) has extended the end date of the term sheet with Chemopharm Limited to acquire the Solwezi East and Chantente exploration licences in the Zambian Copperbelt. The extension to 15 April 2024 allows Chemopharm time to secure the Mining Licences, with Belararox agreeing to contribute US$20,000 to their expenses upon acquisition. The company's decision to support Chemopharm's expenses reflects its dedication to the acquisition and its strategic partnership. Belararox looks forward to the potential acquisition of the Mining Licences and the opportunities it may present for the company's growth and development in the Zambian Copperbelt.